Skip to main content
Cybin Inc. logo

Cybin Inc. — Investor Relations & Filings

Ticker · HELP NEO Manufacturing
Open in API
Filings indexed 441 across all filing types
Latest filing 2025-10-28 Share Issue/Capital Cha…
Country CA Canada
Listing NEO HELP

About Cybin Inc.

http://www.cybin.com

Cybin Inc. is a clinical-stage biopharmaceutical company specializing in breakthrough neuropsychiatry, committed to developing next-generation therapeutics to revolutionize mental healthcare. The company utilizes proprietary drug discovery platforms to innovate Novel Serotonergic Agonists (NSAs)—synthetic molecules designed to activate serotonin pathways and promote neuroplasticity—paired with precision drug delivery systems. A core technological differentiator is the use of deuteration technology to create treatments with consistent delivery and commercial scalability. Cybin maintains a robust intellectual property portfolio, including over 100 granted patents and 250 pending applications, supporting its active drug programs, such as CYB004, currently in Phase 2 clinical trials for the treatment of Generalized Anxiety Disorder. The mission is to provide treatments designed to foster durable improvements in mental health.

Recent filings

Filing Released Lang Actions
Consent letter(s) of other legal counsel.PDF
Share Issue/Capital Change Classification · 1% confidence The document is a legal opinion letter from Bennett Jones LLP filed on SEDAR+ in connection with a prospectus supplement for a common share offering by Cybin Inc. This relates directly to a new share issue/funding transaction rather than an annual report, earnings release, or voting matter. The best match among the available categories is SHA (Share Issue/Capital Change).
2025-10-28 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a registered direct offering of common shares and warrants to raise $175 million, detailing terms of the financing, use of proceeds, and related prospectus information. This is a classic capital-raising update, matching the description for Capital/Financing Update (CAP).
2025-10-28 English
Notice to the Public.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing the launch and retail distribution of a product (CWENCH Hydration™) in new grocery locations. It does not contain financial results, governance changes, capital or dividend announcements, or any specific regulatory form. It is principally an operational update/news release. None of the highly specific categories (10-K, IR, ER, CAP etc.) apply, so it falls into the general “Regulatory Filings” fallback category (RNS).
2025-09-18 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Business Wire press release announcing the completion of enrollment in a Phase 2 clinical study and reaffirming top-line data guidance. It contains forward-looking statements and operational updates on a drug candidate, but no financial results, no earnings data, no detailed investor presentation, no board changes, no share issuance, and no regulatory form filing itself. It is not an earnings release or financial report, nor a formal regulatory submission. It does not fall under any specific category like 10-K, IR, ER, CAP, or MDA. Therefore, by elimination and per the “fallback” rule, it best fits into Regulatory Filings (RNS) as a miscellaneous corporate announcement.
2025-09-08 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing regulatory approval to initiate a Phase 3 clinical trial (EMBRACE) for CYB003 in Europe. It is not a financial or interim report, earnings release, investor presentation, or any of the specific transaction/governance filings. It does not announce dividends, share issues, M&A, board changes, etc. No specific dedicated category exists for a clinical trial approval announcement, so it falls into the general Regulatory Filings fallback category (RNS).
2025-08-07 English
News release - English.pdf
Investor Presentation Classification · 1% confidence The document is a press release announcing Cybin’s participation in an investor‐focused conference (a fireside chat by the CEO), with webcast details. It is not a financial report, regulatory filing, earnings release, or a proxy solicitation. This fits the “Investor Presentation” category (IP), which covers presentations and events for investors.
2025-08-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.